Cerevel Therapeutics Holdings, Inc. financial data

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2024 - 08 May 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1031% % -21%
Debt-to-equity 120% % 47%
Return On Equity -99% % -28%
Return On Assets -45% % -5.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 181,888,631 shares 16%
Common Stock, Shares, Outstanding 181,888,631 shares 16%
Common Stock, Value, Issued $18,000 USD 12%
Weighted Average Number of Shares Outstanding, Basic 181,610,675 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 181,610,675 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $362,885,000 USD 20%
General and Administrative Expense $127,485,000 USD 39%
Operating Income (Loss) $490,370,000 USD -24%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $459,912,000 USD -19%
Income Tax Expense (Benefit) $556,000 USD 62%
Net Income (Loss) Attributable to Parent $460,468,000 USD -19%
Earnings Per Share, Basic -3 USD/shares -7.9%
Earnings Per Share, Diluted -3 USD/shares -7.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $320,436,000 USD 108%
Other Assets, Current $77,000 USD -94%
Assets, Current $859,577,000 USD 2.2%
Property, Plant and Equipment, Net $24,929,000 USD -7.7%
Operating Lease, Right-of-Use Asset $19,667,000 USD -8.2%
Other Assets, Noncurrent $2,619,000 USD -18%
Assets $1,127,343,000 USD 21%
Accounts Payable, Current $10,839,000 USD 48%
Employee-related Liabilities, Current $6,944,000 USD 8.9%
Liabilities, Current $84,104,000 USD 34%
Operating Lease, Liability, Noncurrent $26,866,000 USD -12%
Liabilities $562,888,000 USD 13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,089,000 USD -130%
Retained Earnings (Accumulated Deficit) $1,532,509,000 USD -43%
Stockholders' Equity Attributable to Parent $564,455,000 USD 31%
Liabilities and Equity $1,127,343,000 USD 21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $119,669,000 USD -26%
Net Cash Provided by (Used in) Financing Activities $4,475,000 USD 212%
Net Cash Provided by (Used in) Investing Activities $19,165,000 USD -83%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 181,888,631 shares 16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $322,396,000 USD 107%
Interest Paid, Excluding Capitalized Interest, Operating Activities $4,313,000 USD 0.56%
Payments to Acquire Property, Plant, and Equipment $271,000 USD -19%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $465,245,000 USD -22%
Operating Lease, Liability, Current $3,515,000 USD 16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $2,098,035,000 USD 40%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $1,541,000 USD 17%
Share-based Payment Arrangement, Expense $77,750,000 USD 82%
Interest Expense $10,583,000 USD 0.61%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%